|Supporting innovation and teams in diagnostics, prevention, biomarkers, and therapeutics.||Reactor: Accelerating Clinical and Translational Research|
Reactor is composed of three interdependent components: Innovator, Incubator, and Start Up.
Launched in April 2013, Reactor convenes cross-disciplinary, cross-institutional teams and communities, providing support to expedite C/T research. Reactor helps facilitate skills development, team building, mentoring, funding, and identifies external resources, allowing investigators and teams to translate clinical discoveries. Our ultimate goal is to leverage these discoveries to impact patient care through the development, testing, and adoption of novel prevention strategies, diagnostics, therapeutics, and biomarkers. The result: innovation in clinical and translational research methods and the incorporation of new technologies to improve patient healthcare.
The Reactor program's mission is to:
Researchers can take part in Reactor by participating in the program's three interdependent, yet separate components:
Innovator makes available pilot project funding opportunities to teams that employ novel technologies and methodologies to address significant healthcare issues in their C/T research. Innovator will:
Selected successful teams will progress to the next component of Reactor, Incubator.
With the goal of improving the quality, efficiency, and cost of translation, Incubator will facilitate team building and the formation of large, collaborative communities. At this stage, pilot awardees will work closely and interactively with other research communities within and outside their respective areas.
Incubator leadership and staff will assist selected project teams to identify and access resources and expertise such as the following:
Selected successful teams will progress to the next component of Reactor, Start Up.
To adequately prepare researchers for the successful launch of new ventures, Start Up will provide teams with critical services and resources, including the following:
This late- to mid-stage support serves to propel select teams forward, allowing them to move closer to achieving focused impact such as commercialization, applying for larger grants, practice in community settings, and partnerships with public health agencies. Awardees selected will receive additional funding for up to two years, and receive ongoing support as they complete predetermined milestones and success metrics.
Learn more about a pilot grant opportunity that will provide up to $50,000 funding and access to Ipsen's Targeted Secretion Inhibitor (TSI) technology platform to expand the clinical potential for this novel class of biopharmaceuticals.